Manufacturing Growth & Investment - BioPharma manufacturing has increased by 221% since 2016 [1] - All other manufacturing industries only increased by 38% [2] - BioPharma facilities increased from 1,000 in 2017 to 1,500 [2] - Johnson & Johnson committed to $55 billion of investment in the US [2] Tax Policy Impact - Good tax policy translates into bringing manufacturing jobs back to the US [1] - The 2017 Tax Cuts and Jobs Act (TCJA) provided evidence of this [1] Supply Chain & Production - Johnson & Johnson aims to supply all medicines to US citizens from US facilities by the end of the decade [2] - Building BioPharma manufacturing facilities takes time [2][3] - High-quality and reliable products are essential for patients [3] Government Engagement - The administration is listening and understanding the business [3] - There is an understanding that building these facilities takes time [3]